Emerging drugs for the treatment of irritability associated with autism spectrum disorder

Shamabadi, Ahmad; Karimi, Hanie; Arabzadeh Bahri, Razman; Motavaselian, Mohsen; Akhondzadeh, Shahin

doi:10.1080/14728214.2024.2313650

Cited by 2 publications

(2 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior to the social interaction test, oral administration of 1 mg/kg of the FAAH inhibitor PF-04457845 restored LPS-induced abnormalities in social behavior. A similar improvement was noticed following direct administration of PF-04457845 into the basolateral amygdala, suggesting that altered AEA signaling in this brain area play an important role in transmitting LPS-induced social deficits in at least female mice (Doenni et al, 2016 ; Shamabadi et al, 2024 ).…”

Section: Cbs As a Potential Therapeutic Target Of Asdmentioning

confidence: 62%

Unraveling the Endocannabinoid System: Exploring Its Therapeutic Potential in Autism Spectrum Disorder

Jana,

Nath,

Sen

et al. 2024

Neuromol Med

View full text Add to dashboard Cite

The salient features of autism spectrum disorder (ASD) encompass persistent difficulties in social communication, as well as the presence of restricted and repetitive facets of behavior, hobbies, or pursuits, which are often accompanied with cognitive limitations. Over the past few decades, a sizable number of studies have been conducted to enhance our understanding of the pathophysiology of ASD. Preclinical rat models have proven to be extremely valuable in simulating and analyzing the roles of a wide range of established environmental and genetic factors. Recent research has also demonstrated the significant involvement of the endocannabinoid system (ECS) in the pathogenesis of several neuropsychiatric diseases, including ASD. In fact, the ECS has the potential to regulate a multitude of metabolic and cellular pathways associated with autism, including the immune system. Moreover, the ECS has emerged as a promising target for intervention with high predictive validity. Particularly noteworthy are resent preclinical studies in rodents, which describe the onset of ASD-like symptoms after various genetic or pharmacological interventions targeting the ECS, providing encouraging evidence for further exploration in this area.

show abstract

Section: Cbs As a Potential Therapeutic Target Of Asdmentioning

confidence: 62%

Unraveling the Endocannabinoid System: Exploring Its Therapeutic Potential in Autism Spectrum Disorder

Jana,

Nath,

Sen

et al. 2024

Neuromol Med

View full text Add to dashboard Cite

show abstract

“…Different glutamatergic approaches were considered for the management of ASDs. Riluzole, an inhibitor of voltage-dependent sodium channels and NMDA/kainate receptor antagonist, and memantine, a non-selective NMDA receptor antagonist, were shown to improve ASD symptoms in both children and adult patients [39,40]. The therapeutic properties of low-dose intranasal ketamine, another NMDA receptor antagonist approved as an anesthetic and recently introduced at subanesthetic dose as a rapid-acting antidepressant (see Section 5.1), were also tested in adolescent and young adults with ASD, showing some therapeutic potential with limited and transient adverse effects [41,42].…”

Section: Glutamatergic Drugs For the Treatment Of Autism Spectrum Dis...mentioning

confidence: 99%

Glutamate-Mediated Excitotoxicity in the Pathogenesis and Treatment of Neurodevelopmental and Adult Mental Disorders

Nicosia,

Giovenzana,

Misztak

et al. 2024

IJMS

View full text Add to dashboard Cite

Glutamate is the main excitatory neurotransmitter in the brain wherein it controls cognitive functional domains and mood. Indeed, brain areas involved in memory formation and consolidation as well as in fear and emotional processing, such as the hippocampus, prefrontal cortex, and amygdala, are predominantly glutamatergic. To ensure the physiological activity of the brain, glutamatergic transmission is finely tuned at synaptic sites. Disruption of the mechanisms responsible for glutamate homeostasis may result in the accumulation of excessive glutamate levels, which in turn leads to increased calcium levels, mitochondrial abnormalities, oxidative stress, and eventually cell atrophy and death. This condition is known as glutamate-induced excitotoxicity and is considered as a pathogenic mechanism in several diseases of the central nervous system, including neurodevelopmental, substance abuse, and psychiatric disorders. On the other hand, these disorders share neuroplasticity impairments in glutamatergic brain areas, which are accompanied by structural remodeling of glutamatergic neurons. In the current narrative review, we will summarize the role of glutamate-induced excitotoxicity in both the pathophysiology and therapeutic interventions of neurodevelopmental and adult mental diseases with a focus on autism spectrum disorders, substance abuse, and psychiatric disorders. Indeed, glutamatergic drugs are under preclinical and clinical development for the treatment of different mental diseases that share glutamatergic neuroplasticity dysfunctions. Although clinical evidence is still limited and more studies are required, the regulation of glutamate homeostasis is attracting attention as a potential crucial target for the control of brain diseases.

show abstract

Emerging drugs for the treatment of irritability associated with autism spectrum disorder

Cited by 2 publications

References 102 publications

Unraveling the Endocannabinoid System: Exploring Its Therapeutic Potential in Autism Spectrum Disorder

Unraveling the Endocannabinoid System: Exploring Its Therapeutic Potential in Autism Spectrum Disorder

Glutamate-Mediated Excitotoxicity in the Pathogenesis and Treatment of Neurodevelopmental and Adult Mental Disorders

Contact Info

Product

Resources

About